Thanks Ahmed for your answer on Anthera.
Thought it might be of interest to look at other companies which are in the GBPB field according to this report
http://www.researchandmarkets.com/research/wwbhdn/glomerulonephritis
For some, I’ve added information on what appears to be relevant research.
Alexion Pharmaceuticals, Inc.
Share price $124
Market cap $29.13b
Amyndas Pharmaceuticals LLC
Revenue 300k/yr
Anthera Pharmaceuticals Inc.
Share price $3
Market cap 129.7m
Avexxin ASBiogen, Inc.
Share price $296
Market cap $64b
Complexa, Inc.
Complexa’s nitro and keto-fatty-acid anti-inflammatory human cell signaling technology stems from Nobel Prize winning research and a top 10 cited scientist in the field of biochemistry and pharmacology. The Company is led by highly experienced and prominent serial entrepreneurs in the healthcare industry.
Dimerix Bioscience Pty Ltd
Escala Therapeutics, Inc.
Share price 2.38
Market cap $116m
a majority-owned subsidiary of Fortress Biotech, Inc., is a development stage company focused on the clinical development and commercialization of therapies for orphan disorders. We are currently developing N-acetyl-D-mannosamine (ManNAc) for the potential treatment of GNE myopathy and primary podocyte (glomerular) disorders in collaboration with NIH researchers.
Glomerulopathies:
• Steroid resistant/dependent MCD/FSGS - 800-6,000 new patients each year, 6,000 children
live with disease, 20,000 patients have end stage kidney disease due to MCD/FSGS
• Diabetic nephropathy - 200,000 patients
Potential competition:
• Ultragenyx has initiated a Phase 3 trial of oral sialic acid, dosed as extended release formula
3 times daily, as a potential treatment for GNE Myopathy/HIBM
• Evidence of effect in Phase 2 study enrolling patients with GNE Myopathy with preserved
lower extremity function (baseline 6-Minute Walk Test > 200m)
• Currently no known development of ManNAc by institutions other than NIH for glomerular
diseases
FibroStatin
FibroStatin has used rational drug design to identify FST12, a First-in-Class small molecule inhibitor of GPBP that targets the high molecular weight oligomers of GPBP that appear during EMT and other pathological conditions. FST12 significantly reduces tumor growth and metastasis in numerous animal models. Also, initial dose ranging toxicity studies show a substantial safety margin.
SLGlaxoSmithKline
Share price $42.50
Market cap $106.4b
Mallinckrodt Plc
Share price $73.07
Market cap $7.87b
Merck KGaA
Share price $62.49
Market cap $173m
Omeros Corporation
Share price $10.94
Market cap $474m
Pharmalink AB
unknown
Pfizer Inc.
Share price $34.10
Market cap $206b
Retrophin Inc.
Share price $21.21
Market cap $782m
Sep 8, 2016 - Ligand Pharmaceuticals Incorporated LGND said that its partner Retrophin, Inc. RTRX announced positive top-line results from a phase II study. The DUET study is evaluating their pipeline candidate sparsentan for the treatment of a rare kidney disorder, focal segmental glomerulosclerosis (FSGS).
Rigel Pharmaceuticals, Inc.
Share price $3.29
Market cap $300m
Shire Plc
Share price $185
Market cap $54b
Toray Industries, Inc.
unknown
Variant Pharmaceuticals, Inc
Share price $28.06
Market cap $9.75b
Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200. VAR 200 has potential for treating multiple indications associated with the damaging effects of cellular accumulation of cholesterol and lipids on the kidney, including focal segmental glomerulosclerosis (FSGS), a rare disease affecting up to 133,000 people in the United States.
(20min delay)